STAT+: AstraZeneca picks up FDA approval for hypertension drug

The China question, FDA leadership shakeups, and other biotech news from The Readout Alastair Grant/AP Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we’re bringing you a special report: a fascinating look at how China’s growing role in global drug development is deeply dividing the U.S. biotech industry, with executives openly debating whether reliance on Chinese partners is a competitive necessity or a national security risk. Meanwhile, the FDA’s leadership shakeup has widened, with both CBER and CDER getting new acting directors, among other changes. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Meghana Keshavan covers biotech and contributes to The Readout newsletter.